Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Glycoursodeoxycholic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.74 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.67 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.83 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.83 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.83 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycoursodeoxycholic Acid SCHEMBL61042 | 1.00 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL29366725 | 1.00 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL2020307 | 0.99 | GPBAR1 (0.82) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL178105 | 0.98 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL935341 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL9151495 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL59881 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL12917601 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycochenodeoxycholate SCHEMBL236354 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| SCHEMBL19104663 | 0.91 | GPBAR1 (0.86) | GPBAR1NR1H4ABCB11ENPP2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119000956-A | Kit for simultaneously detecting 15 bile acid spectrums and 3 bile acid precursors in serum and detection method | 上海捷易生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240325458-A1 | COMPOSITION FOR PRODUCING BILE ACIDS | KEIO UNIVERSITY (JP) | 2024-10-03 | — | — | US | disclosed |
| CN-115279889-B | Composition for producing bile acid | 庆应义塾 | 2024-09-10 | — | — | CN | disclosed |
| CN-116672349-A | Pharmaceutical composition for treating or improving polycystic ovary syndrome | 澳门科技大学 | 2023-09-01 | — | — | CN | disclosed |
| CN-113604446-B | Mutant R16Q of 7 alpha-hydroxysteroid dehydrogenase St-2-2 | 重庆大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-112322596-B | 7 alpha-hydroxysteroid dehydrogenase mutant J-1-1 delta C6 and application thereof | 重庆大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-112175918-B | 7 alpha-hydroxysteroid dehydrogenase mutant St-2-2 delta C10 and application thereof | 重庆大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-112251418-B | Enzyme for specifically catalyzing CDCA and conjugate thereof and application thereof | 重庆大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-115279889-A | Compositions for the production of bile acids | 庆应义塾 | 2022-11-01 | — | — | CN | disclosed |
| CN-113430183-B | Mutants of 7 alpha-hydroxysteroid dehydrogenase St-2-2T15G, T15S and T15A | 重庆大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-114555092-A | Application of bile acid and derivatives thereof in preparing GPR39 agonist | 北京大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-113604446-A | Mutant of 7 alpha-hydroxysteroid dehydrogenase St-2-2R16Q | 重庆大学 | 2021-11-05 | — | — | CN | disclosed |
| CN-113430183-A | Mutants of 7 alpha-hydroxysteroid dehydrogenase St-2-2T15G, T15S and T15A | 重庆大学 | 2021-09-24 | — | — | CN | disclosed |
| CN-112322596-A | 7 alpha-hydroxysteroid dehydrogenase mutant J-1-1 delta C6 and application thereof | 重庆大学 | 2021-02-05 | — | — | CN | disclosed |
| CN-112251418-A | Enzyme for specifically catalyzing CDCA and conjugate thereof and application thereof | 重庆大学 | 2021-01-22 | — | — | CN | disclosed |
| CN-112175918-A | 7 alpha-hydroxysteroid dehydrogenase mutant St-2-2 delta C10 and application thereof | 重庆大学 | 2021-01-05 | — | — | CN | disclosed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | disclosed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325458-A1 | COMPOSITION FOR PRODUCING BILE ACIDS | CYP46A1, CYP7A1, HSD17B12 | NR3C1 3298/4885CA1 1281/4885CA2 1066/4885 |
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | NR3C1 3131/4885CA1 4506/4885CA2 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.